Lumateperone (Caplyta) and Ketamine Therapy | Tovani Health
Caplyta (Lumateperone) — Atypical antipsychotic (schizophrenia, bipolar depression)
Verdict at Tovani Health
Compatible; same D2-attenuation framework as other atypicals.
Lumateperone and ketamine are compatible. As a newer atypical antipsychotic approved for schizophrenia and bipolar depression, lumateperone has a lighter metabolic and EPS profile than older atypicals. The theoretical D2-attenuation of ketamine's antidepressant response applies as it does for other atypicals.
If you take Caplyta regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Caplyta interacts with ketamine
Lumateperone modulates serotonin, dopamine, and glutamate. Unique mechanism with presynaptic D2 partial agonism. CYP3A4 substrate.
What we do at intake
Disclose dose and indication. Tell us about any other CYP3A4 modulators you take.
Bottom line
Lumateperone and ketamine are compatible. As a newer atypical antipsychotic approved for schizophrenia and bipolar depression, lumateperone has a lighter metabolic and EPS profile than older atypicals. The theoretical D2-attenuation of ketamine's antidepressant response applies as it does for other atypicals.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Caplyta (Lumateperone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression. Veraart JKE, Smith-Apeldoorn SY, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 17, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.